

BIO CHINA | Korea

Global Forum | Seoul

July 9-10, 2026 Seoul, Korea

14, Magokjungang8-ro, Gangseo-gu, Seoul, Republic of Korea



500+

Attendees

300+

Companies

50+

Speakers

About BIOCHINA

Following the success of **BIOCHINA 2025**, which welcomed **30,000 attendees** in Suzhou, BIOCHINA continues its journey of **innovation and collaborative growth**.

Over the past decade, BIOCHINA has expanded from China's thriving biopharmaceutical sector to the **global stage**, establishing an international platform that **connects industry players** and **unites global expertise** to drive collaboration.

Through **technological breakthroughs, commercial implementation, capital support, and ecosystem integration**, BIOCHINA has witnessed China's innovative drug industry evolve from **follower to leader**, advancing in step with the industry and the times

About BIOCHINA Global Forum @ Korea 2026

After a successful inaugural edition in 2025, BIOCHINA Global Forum @ Korea 2026 will significantly scale up from a one-day event to a two-day program, while increasing attendance from 300 participants to over 500 attendees. The 2026 forum will also bring together 300+ companies and 50+ speakers to foster deeper exchange and collaboration across the China-Korea biotech ecosystem.






500+
Attendees














300+
Companies



50+
Speakers



BIOCHINA Global Forum @ Korea 2026



BIOCHINA Global Forum @ Korea 2026

ORGANIZER



CO-ORGANIZER



서울경제진흥원

SPONSOR



BIOCHINA Global Partner



Time

July 9th & 10th, 2026

Scale

500+ Attendees,
over 200 Chinese and Korean companies

Featured Participations

- ✓ **Exhibitor:** Showcase your company at the BIOCHINA Global Forum @ Korea 2026
- ✓ **Registration:** BIOCHINA Partnering, Conference Pass
- ✓ **Roadshow Session:** Apply for the technology showcase of roadshow presentation
- ✓ **Afterparty:** Networking event for both Chinese and Korea companies



Event Overview

Roadshow Room

Day 1 – July 9 | Afternoon

13:00 -14:00 | Company Matchmaking Session

14:00-15:00 | Service Provider Roadshow

15:20 -16:20 | Biotech and Biopharma Innovation & Investment Showcase

Day 2 – July 10 | Morning

9:00- 10:30 | China Biopharma Innovation & Investment Showcase

Day2 – July 10 | Morning

10:30-12:00 | CGT Closed-Door Meeting

Forum Room

Day 1 – July 9 | Morning

9:00-12:00 | BD & Collaboration Between China and Korea

Day 1 – July 9 | Afternoon

13:00-17:00 | Innovative Therapeutics & R&D Collaboration - Antibody Drugs and XDCs

Day 2 – July 10 | Morning

9:00-12:00 | Global Clinical Development

Day 2 – July 10 | Afternoon

13:00-16:40 | Cell & Gene Therapy Innovations & R&D Collaboration

Day 1 – July 9 | Morning



Ellen Jooyeon Kim
KDDF
Director, Global Partnership & BD



Jielun Zhu
Excalipoint Therapeutics
Co-Founder, CFO & CBO



Runxie Li
HLC, Korea
Representative



Gi Soo Kang
BNH Investment
Bio/Healthcare VC investor



Jenny Yang
Novo Nordisk
Head of External Innovation Asia Pacific



Christina Baek
Novartis Korea,
Innovation & Global BD Lead



Kevin Huh
KIMCo
CEO



Peng Zang
CARsgen
VP, Strategic Planning
Head of BD



Eric J. Maeng
Hanmi Science Co., Senior
Director, Launching & Development Strategy



June Hahn
Boehringer Ingelheim
Head of BD&L Korea



Jae-young Ha
AriBio
Senior Vice President R&BD



Billy Cho
CBC Group, Senior
Managing Director



Gang Qin
GeneQuantum
CEO



Vivian Feng
Fosun pharma
General Manager of BD

BD & Collaboration Between China and Korea

09:00–09:10 | Opening Remarks – Organizer and Local Partners

Haengshin Lee, Director General of KHIDI.

Vera Deng, CEO, Enmore Bio

09:10–09:30 | Keynote Presentation – China & Korea Biotech and Pharma Market Landscape

Overview of China and Korea biotech markets: size, policy, regulatory environment, clinical ecosystem, innovation trends, and BD opportunities.

Speaker: Ellen Jooyeon Kim, Korea Drug Development Fund (KDDF), Director, Global Partnership & Business Development Division

09:30–10:10 | Panel Discussion – China–Korea Collaboration Opportunities and Investment Trends

Discussion on cross-border collaboration models, VC priorities, emerging technologies (ADC, CGT, AI-driven drug discovery), and partnership structuring.

Moderator: Ellen Jooyeon Kim, Korea Drug Development Fund (KDDF), Director, Global Partnership & Business Development Division

Panelist: Jielun Zhu, Excalipoint Therapeutics, Co-Founder, CFO & CBO

Gi Soo Kang, BNH Investment, Bio/Healthcare VC investor

Runxie Li, HLC, Korea Representative

Billy Cho, CBC Group, Senior Managing Director

10:10–10:30 | Tea Break & Networking

10:30–11:10 | Panel Discussion – BD Deals and Licensing Case Studies – MNCs and big pharma

Insights on recent China–Korea licensing deals and strategic partnerships: deal structures, collaboration models, and lessons learned.

Moderator: Kevin Huh, KIMCo, CEO

Panelists: Jenny Yang, Novo Nordisk, Head of External Innovation Asia Pacific

June Hahn, Boehringer Ingelheim, Head of BD&L Korea

Christina Baek, Novartis Korea, Innovation & Global BD Lead

Eric J. Maeng, Hanmi Science Co., Senior Director, Launching & Development Strategy

11:10–12:00 | Panel Discussion – Innovative Collaboration Models of Biotech

Moderator: Jielun Zhu, Excalipoint Therapeutics, Co-Founder, CFO & CBO

Panelists: Peng Zang, CARsgen, Vice President, Strategic Planning, Head of Business Development

Gang Qin, GeneQuantum, CEO

Vivian Feng, Fosun pharma, General Manager of BD

Jae-young Ha, AriBio, Senior Vice President R&BD

12:00–13:00 | Lunch

Day 1 – July 9 | Afternoon



Pengfei Zhou

WUHAN YZY BIOPHARMA CO
 LTD., Founder&
 Chairman &CEO



Nam Gu Her

AIMED BIO, CEO



Sun Bae Lee

Alteogen,
 Senior Vice
 President



Gang Qin

GeneQuantum, CEO



Sang Jeon Chung

AbTis Co. Ltd., CSO



Won Bae Jeon

Excellamol Inc, CEO



Shun Luo

Thousand Oaks Biologics,
 Founder, Chairman and
 President



Hyunsu Park

Celltrion
 Head of CMC Regulatory
 Affairs Department

Innovative Therapeutics & R&D Collaboration – Antibody Drugs and XDCs

13 :00 -13:20 | Keynote Presentation – M701 (EpCAM×CD3): A Novel T-Cell Engager for Malignant Ascites and Pleural Effusion

Speaker: Pengfei Zhou, WUHAN YZY BIOPHARMA CO., LTD., Founder& Chairman &CEO

13 :20 -13:40 | Keynote Presentation – TBD

13:40-14:00 | Keynote Presentation – Subcutaneous delivery of ADC by use of ALT-B4; Novel Hyaluronidase

Speaker: Sun Bae Lee, Alteogen, Senior Vice President

14:00-14:20 | Keynote Presentation – Design and Development of Dual-Payload and Bispecific ADCs

Speaker: Nam Gu Her, AIMED BIO, CEO

14:20-14:40 | Keynote Presentation – AT-211 ADC targeting CLDN18.2 for gastric cancers prepared by AbClick, a site-selective linker

Speaker: Sang Jeon Chung, AbTis Co. Ltd., CSO

14:40 -15: 00 | Keynote Presentation – Industrialization Imperative: Redefining the Value Chain for the Next Generation of Biomanufacturing

Speaker: Shun Luo, Thousand Oaks Biologics, Founder, Chairman and President

15:00 -15:20 | Keynote Presentation – Avoiding CMC Pitfalls in Antibody Development: Insights from FDA CRLs

Speaker: Hyunsu Park, Celltrion, Head of CMC Regulatory Affairs Department

15:20 -15:40| Tea Break and Networking

15:40-16:20 | Panel Discussion - R&D of Bispecific Antibodies & XDCs: Future Directions and Korean Industry Insights

Panelist : Won Bae Jeon, Excellamol Inc, CEO

Sang Jeon Chung, AbTis Co. Ltd., CSO

16:20 -17:00 | Panel Discussion-Accelerating the Biospecific Antibody & XDC Race: Global Landscape with China Focus and Differentiation Strategies

Panelist : Gang Qin, GeneQuantum, CEO

Pengfei Zhou, WUHAN YZY BIOPHARMA CO., LTD., Founder& Chairman &CEO

Day 2 – July 10 | Morning



Wei Zhu
BioRay
Pharmaceutical Co
Ltd.
Chief Medical
Officer



Jinjin Liang
Beijing Mab-Works Co Ltd.
Chief Medical Officer



Steve Chin
MediLink Therapeutics
CMO

Global Clinical Development

9: 00 -10: 00 | CMO Perspectives on Global Clinical Development

How Chinese Biopharma CMOs Drive Global Clinical Development

Global Clinical Development Strategies: Insights from Chinese Biopharma CMOs

Panelist: Wei Zhu, BioRay Pharmaceutical Co., Ltd., Chief Medical Officer

Jinjin Liang, Beijing Mab-Works Co Ltd., Chief Medical Officer

Steve Chin, MediLink Therapeutics, CMO

10: 00-11: 00 | Navigating Korea's Clinical Development Landscape and Opportunities-Collaborate with the KCDA (Korea Clinical Development Association)

Korea Clinical Trial Ecosystem & Regulatory Pathway

Strategic Advantages of Conducting Clinical Trials in Korea

11: 00-11: 20 | Tea Break and Networking

11: 20-11: 40 | Keynote Presentation: Clinical Development in China: Strategies & Practical Routes

speaker: Jinjin Liang, Beijing Mab-Works Co Ltd., Chief Medical Officer

11: 40-12: 00 | Keynote Presentation: TBD

speaker: Steve Chin, MediLink Therapeutics, CMO

12: 00-13: 00 | Lunch

Day 2 – July 10 | Afternoon



Lin Yang

PersonGen
BioTherapeutics (Suzhou)
Co.,Ltd. Founder,
Chairman, CEO



Zonghai Li

CARsgen,
Founder&CEO



Yoojun Nam

Yipscell Inc., CTO



Paul Song

NKGenBiotech,
Inc, Chairman
and CEO



Xiaowen He

Oricell Therapeutics
Co.,Ltd, Co-founder and
Chief Scientific Officer



Jae Hun Shin

Yonsei University,
Associate Professor



Seong-Wook Lee

Rznomics Inc,
President & CEO



Xiangrong Song

WestGene Biopharma
Co Ltd, CEO



Chunlin Zhao

AnlongBio
Founder



Meehyun Jung

CTX, Inc.
Head of Development
Division

Cell & Gene Therapy Innovations & R&D Collaboration

13:00 – 13:20 | Keynote Presentation – Advances in In Vivo CAR Breakthrough in Lentiviral Vector-based in vivo CAR Technology

Speaker: Lin Yang, PersonGen BioTherapeutics (Suzhou) Co., Ltd. Founder, Chairman, CEO

13:20 – 13:40 | Keynote Presentation – Technology advancement and clinical application of CAR-T Cell Therapy

Speaker: Zonghai Li, CARsgen, Founder &CEO

13:40 – 14:00 | Keynote Presentation – Use of Troculeucel (Cryopreserved Enhanced Autologous NK Cell Therapy) for Neurodegenerative Diseases.

Speaker: Paul Song, NKGen Biotech, Inc., Chairman and CEO

14:00 – 14:20 | Keynote Presentation – Korea's Excellence in Bio-manufacturing: Advanced CMC and Quality Strategies for Global Success

Speaker: Meehyun Jung, CTX, Inc., Head of Development Division

14:20 – 14:40 | Keynote Presentation – Next-generation CAR-T therapeutics for precision medicine.

Speaker: Xiaowen He, Oricell Therapeutics Co.,Ltd, Co-founder and Chief Scientific Officer

14:40 – 15:00 | Keynote Presentation – RNA Editing Therapeutics through Catalytic RNA Rewriting: From Platform to Clinic

Speaker: Seong-Wook Lee, Rznomics Inc, President & CEO

15:00 – 15:20 | Keynote Presentation – From mRNA Cancer Vaccines to In Vivo CAR-T: Delivery-Driven Innovation and Clinical Translation

Speaker: Xiangrong Song, WestGene Biopharma Co., Ltd, CEO

15:20 – 16:00 |Panel Discussion – Future Directions in CGT Technology

Moderator: Lin Yang, PersonGen BioTherapeutics (Suzhou) Co., Ltd. Founder, Chairman, CEO

Panelist: Xiaowen He, Oricell Therapeutics Co.,Ltd, Co-founder and Chief Scientific Officer

Xiangrong Song, WestGene Biopharma Co., Ltd, CEO

Chunlin Zhao, AnlongBio, Founder

16:00 – 16:40 | Panel Discussion – Korea CGT Panel

Moderator: Jae Hun Shin, Yonsei University, Associate Professor of Bio-Convergence Integrated Science & Engineering Division Underwood International College

Panelist: Yoojun Nam, Yipscell Inc., CTO

Roadshow and Closed-Door Meeting Agenda

Day 1 – July 9 | Afternoon

13:00-14:00 | Company Matchmaking Session

13:00-13:30 | Fosun Pharma Session: Vivian Feng, General Manager of BD, Eric Huang, CFO

13:30-14:00 | DongKoo Bio&Pharm

14:00-15:00 | Service Provider Roadshow

14:00-14:10 | Next-Generation Cell Culture Solutions Empowering Modern Biomanufacturing

14:10-14:20 | Crown Bioscience

15:20-16:20 | Biotech and Biopharma Innovation & Investment Showcase

Guests: June Hahn, Boehringer Ingelheim, Head of BD&L Korea

Runxie Li, HLC, Korea Representative

15:20-15:40 | Vignovita Innovative Pipeline Introduction

15:40-16:00 | Polymer-Free Magnetic Nanobead Platform for Next-Generation Biomarker Enrichment and Liquid Biopsy

16:00-16:15 | Project2:

16:15-16:30 | Project3:

Day 2 – July 10 | Morning

9:00-10:30 | China Biopharma Innovation & Investment Showcase

Guest: Runxie Li, HLC, Korea Representative

9:00-9:15 | First-in-class Cell-free Protein Biologics Project for Neuro-Restorative and Regenerative Medicine

9:15-9:30 | CLDN18.2 Targeting CAR-T Therapy for Treatment of Advanced Gastrointestinal Cancer

9:30-9:45 | Organ Targeting siRNA Therapeutics and complex delivery systems for treatment of Hemophilia, IPF, AD and Schizophrenia

9:45-10:00 | FIC/BIC IRAK4 degrader

10:00-10:15 | In vivo cell reprogramming based Cancer Therapy and Regenerative Medicine

Day2 – July 10 | CGT Closed-Door Meeting Agenda

Co-Host:



Zonghai Li
CARsgen,
Founder&CEO



Yun Kyoung Kang
DIPS project/ Korea Institute
of Toxicology Mentor/GAIA-BT,
Inc. CEO

10:30-10:50 Opening Session – Opening remarks and introductions by key representatives from both China and South Korea.

10:50-11:10 Interpretation and Alignment of CGT Regulatory Policies Between China and South Korea

This session will cover the unique features and strengths of each country's policies, including their regulatory frameworks, approval standards, and clinical translation support mechanisms.

11:10-11:40 CGT Paths for Industrial Collaboration and Clinical Empowerment

Industrial Collaboration: Based on their corporate strategies, participants will explore complementary opportunities in the China-South Korea CGT sector (e.g., technology, supply chain, market access) and articulate cooperation needs such as joint R&D, technology licensing, and market expansion.

Clinical Empowerment: Chinese and Korean CROs and clinical experts will discuss strategies and opportunities to support companies in establishing clinical trials across both markets, with a focus on facilitating cross-border trial implementation and driving collaborative industrial growth.

11:40-12:00 Open Discussion & Networking

Confirmed Participants

Jianshi Kechuang (Guangzhou) Biopharmaceutical Development Co., Ltd./Chairman of the Board//Mao lili

Suzhou Axcel Pharmaceuticals Ltd. /CEO/Xudong Yuan

Wuhan YZY Biopharma Co., Ltd./BD Director/Jing Wang

Wuhan YZY Biopharma Co., Ltd./CEO/Pengfei Zhou

Neuregen Therapeutics/Co-founder & CSO/Yueguang Liu


Oricell Therapeutics Co.,Ltd/Co-founder and CSO/Xiaowen He

PersonGen/Founder, Chairman, CEO/Lin Yang

Darwin Biotechnology Ltd./CBO/Michael Chen

CTX, Inc., /Head of Development Division/ / Meehyun Jung

NKGen Biotech, Inc./ Chairman and CEO/ Paul Song



This image is not the final version of the booth layout. All rights of final interpretation belong to Enmore Bio

Sponsorship

- Session Sponsorship 1hr - \$11,200

Exhibitor

- Exhibitor Package – \$7,500
Conference, BIOCHINA Partnering

Roadshow

- Roadshow (Biotech & Pharma) – \$1,000
- Roadshow package– (Service Providers) – \$7,000

Month	BIOCHINA Partnering Pass (One-on-One Meetings)	Conference Pass
June	Full Price → \$700	Full Price → \$300
July	Full Price → \$700	Full Price → \$300



BIO CHINA

Global Forum

Korea

Seoul

July 9-10, 2026 Seoul, Korea

14, Magokjungang8-ro, Gangseo-gu, Seoul, Republic of Korea



Mobile Portal



Registration